How will you use REGEN-COV (casirivimab/imdevimab-monoclonal antibody treatment recently approved under EUA as post-exposure prophylaxis for Covid) in rheumatic patients on immunosuppressive therapy?  

Would you consider this for patients on B-cell depleting therapies or more broadly for other immunosuppressive agents?



Answer from: at Academic Institution

Answer from: at Community Practice